1. Pink Sheet
  2. >>Biosimilars & Generics
  3. >>Generics

Was Coronavirus A Factor In US FDA Approval Of Proventil HFA First Generic?

 
• By Derrick Gingery

The agency said Cipla’s ANDA met all the requirements for approval, but also that there is increased demand for the products.

FDA Approved typed words on a vintage typewriter
The US FDA's approval of the first generic of Proventil HFA came as there are worries about product shortages. • Source: Shutterstock

The US Food and Drug Administration suggested that its approval of the first generic version of Merck & Co. Inc.’s Proventil HFA (albuterol sulfate) metered dose inhaler may have at least some connection to the coronavirus outbreak.

Cipla Ltd.’s ANDA for the product, which is indicated for treatment or prevention of bronchospasm and exercise-induced bronchospasm, was approved 8 April

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Biosimilars & Generics

EU Biosimilar Filings, Opinions And Approvals

 
• By Neena Brizmohun

A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.

Pulling Together: Global Regulators Discuss Convergence On Biosimilars

 
• By Dave Wallace

While the biosimilars industry has welcomed individual pockets of progress around regulatory streamlining, it is essential that approaches from global authorities move forward together if they are to have a meaningful impact on biosimilar development. At Medicines for Europe’s annual biosimilars conference, regulators from around the world talked about how their thinking is converging.

Beyond Tariffs: The Silver Lining Of The US Pharma Security Investigation

 
• By Jessica Merrill

An investigation by the US Secretary of Commerce into pharmaceutical imports gives industry an opportunity to comment. AAM CEO John Murphy talked to Pink Sheet's sister publication Scrip about the latest developments.